The Report
Deep dives into company funding, growth strategies, and market insights from the world's most innovative businesses
6 reports and counting
Torl Biotherapeutics Raises $96M in Series C
Torl Biotherapeutics, a Biotech company based in Los Angeles, CA, has raised $96M in Series C at a $500M valuation led by Cormorant Asset Management, BVF Partners.
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
TORL BioTherapeutics Raises $96M Series C to Transform Biotech
TORL BioTherapeutics has secured $96M Series C in funding to accelerate growth and innovation in the biotech sector. Immunology company developing T cell engager therapies for cancer and autoimmune diseases...
Atara Biotherapeutics Headquarters - Office Location & Address
Discover Atara Biotherapeutics's headquarters at 611 Gateway Blvd, South San Francisco, CA 94080. T-cell immunotherapy developer. Learn about the office facilities and work environment.
Latigo Biotherapeutics Raises $135M Series A to Transform Biotech
Latigo Biotherapeutics has secured $135M Series A in funding to accelerate growth and innovation in the biotech sector. Pain management company developing non-opioid therapies for chronic pain conditions...
Seaport Therapeutics Raises $225 Million in Series B - October 21, 2024
Seaport Therapeutics announced $225 Million in Series B funding at a Undisclosed valuation. Seaport Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for neuropsychiatric disorders using prodrug technology ...
Showing 6 reports • Page 1 • Category: all
Stay ahead of the market
Get weekly insights delivered to your inbox. No spam, just intelligence.